PaTHway Phase 3 Trial Analysis

Baseline Conventional Therapy Conventional Therapy Total Daily Dose (TDD) at Baseline Calcium Supplement/TDD (mg) (n) Mean Min, Max Calcitriol (Active Vitamin D) /TDD (µg) (n) Mean Min, Max Alfacalcidol (Active Vitamin D) /TDD (µg) (n) Mean Min, Max TransCon PTH (N = 61) Placebo (N = 21) 21 61 1748 2105 600, 5000 800, 7200 53 17 0.76 0.69 0.5, 2.0 8 0.5, 1.75 4 2.0 2.5 1.0, 4.0 1.5, 2.5 2 patients did not have eDiary information confirmed by prescription information. 13 Data on file, Ascendis Pharma 2022. TransCon PTH is an investigational product candidate. For investor communication only. Not for use in product promotion. Not for further distribution. Pathway TRIAL ascendis pharma

View entire presentation